Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
People found value in fatty acids centuries before modern chemistry offered a fuller explanation. Extraction of oleic acid from olive oil dates back to apothecaries and herbalists, who prized its physical properties in salves and ointments. Chemists later purified and defined its structure, carrying research well into the twentieth century. The fusion between oleic acid and polyoxometalates began as researchers looked for ways to stabilize and deliver complex metal clusters in medicine and catalysis. With time, the pharmaceutical world caught on, realizing the synergetic value between fatty acids and metal-oxide clusters, paving the way for grade-specific products that now serve regulatory standards such as BP, EP, and USP.
Oleic Acid Polyoxometalate Pharma Grade, referenced under varying regulatory monographs, combines the well-known benefits of oleic acid with the unique chemical features of transition metal oxide clusters. Unlike the pure acid, these polyoxometalates lend new chemical reactivity and targeted stability—a boon for specific pharmaceutical synthesis and drug delivery tasks. Pharmaceutical developers have come to rely on this compound for its reliable composition and batch-to-batch reproducibility, critical for downstream applications involving strict testing and patient safety.
Pure oleic acid typically runs clear with a faint yellow hue, but the introduction of polyoxometalates flips the narrative. Depending on the metal core chosen, the product presents varying colors and consistencies. Melting points fluctuate by composition, but many forms hold stable above room temperature, resisting crystallization even in long-term storage. Solubility characteristics shift: the product absorbs better in organic phases, and its reactivity opens doors for modifications not accessible by fatty acids alone. Given the chemical robustness of polyoxometalate clusters, shelf lives stretch for months, sometimes years, under standard pharmaceutical storage conditions, outpacing common excipients.
Regulatory monographs like BP, EP, and USP set out strict standards. Each batch requires testing for lead, arsenic, cadmium, and heavy metals, with limits far tighter than for industrial grades. Manufacturers print batch numbers, production dates, and expiration periods directly on labels. Full traceability, from precursor materials through synthesis to packaging, remains non-negotiable. Pharmacies and formulation houses expect clear documentation for each technical metric: purity (typically exceeding 99.5%), residual solvent analysis, standardized moisture content, and metal content, if relevant to function. Mislabeling or data gaps can mean a lost client or—worse—regulatory penalties.
Moving from raw oleic acid to pharma-grade material takes more than simple distillation. Chemists start with rigorously tested vegetable sources, purifying: removing pesticides, proteins, and natural dyes. At the lab scale, they use solvent extraction, followed by reaction with polyoxometalate anions—often under nitrogen to protect sensitive metals. Reactor pH and temperature dial in to avoid hydrolysis. During scale-up, process engineers add filtration—sometimes using activated charcoal or micron filters. Residual solvents evaporate under vacuum, with samples checked at each stage. Experience in the plant tells: operational slips here can contaminate an entire batch, sending raw material costs up and batch rework times into the red.
Chemists enjoy tinkering. Oleic Acid Polyoxometalate stands as a flexible platform for downstream modifications. Adding additional functional groups to the oleic backbone creates derivatives suited for targeted drug delivery. Further metal cluster modifications tune catalytic activity as needed for research enzymes or imaging agents. Acid stability matches tough reaction conditions, meaning the product tolerates sterilization and chemical ripening steps without breakdown. Drug companies sometimes link these molecules covalently to peptides or small molecule drugs, reaching new heights for solubility or permeability—a far cry from what basic fatty acids offered a generation ago.
Pharma-grade Oleic Acid Polyoxometalate hides behind trade names depending on the manufacturer and region. International suppliers showcase a shelf of brand variations. Some use historical names, tracing roots to early patent filings; others lean on IUPAC nomenclature or shortcut chemical codes. This scattering of names creates headaches for procurement and regulatory filing. Standardizing references to major pharmacopeia monographs cuts confusion, making regulatory audits and international collaborations run smoother. Even so, industry insiders recognize the formula as their main anchor: oleic acid partner to their chosen metal-oxide cluster.
Working with fatty acid derivatives at scale can trip up the unprepared. Polyoxometalates, by their nature, call for careful handling, as metal residues or dust sometimes irritate skin or mucous membranes. Plant safety protocols mandate gloves, splash goggles, and proper ventilation in weighing and reaction areas. Fire safety catches attention too—many batches ride in flammable solvent carriers or get blended with other reactive organics. Pharmacies running final formulation must respect these same risks, recognizing the slim but real hazards associated with high-purity excipients. Training, data sheets, and batch-specific risk assessments become tools, not just regulatory paperwork, for keeping lines running and people healthy.
Drug developers increasingly turn to Oleic Acid Polyoxometalate when striving for tricky formulation targets. Its unique metal core helps shuttle biologically active cargoes across membranes that block other compounds, making it a favorite for designing controlled-release formulations or targeted therapies. The product’s ability to shield drugs from early breakdown scores points in oral forms and in parenteral suspensions, stretching shelf life and broadening patient access. Industrial chemists tap into the compound’s chemical versatility for specialty syntheses where classic acids fail by breaking down or clogging reactors. Even academic labs see fresh potential, plugging the compound into experimental systems that mimic cell membranes or explore metal-cluster chemistry.
Investments in research span decades, with journals now full of papers exploring tweaks to both the fatty acid tail and the metal cluster. Some teams probe new bioactivity, screening analogues against common pathogens or cancer cell lines. Others zero in on how structural changes shift pharmacokinetics. Larger companies put serious cash behind labs figuring out better purification or green chemistry approaches—aiming at both cleaner products and trimmed costs. Collaborations cross borders, blending insights from analytical chemistry, nanotechnology, and molecular pharmacology. From sometimes messy pilot trials emerge generations of better, safer, more precisely targeted versions.
Every chemical brings its risks, and manufacturers cannot take safety for granted. Animal studies and cell assays set the baseline: researchers look for dose-dependent toxicity, accumulation patterns, and possible breakdown products. While the base oleic acid stands as a well-tolerated compound in food and pharma, adding polyoxometalate groups muddies predictions. Regulators demand extensive genotoxicity, allergenicity, and reproductive toxicity data before stamping approval. Transparency in publishing negative as well as positive findings helps build trust and keeps careers honest. Companies that cut corners or under-report run more than just PR risks—they can face product withdrawal and criminal prosecution in the worst cases.
Looking ahead, both challenges and promise lie ahead. Automation and advanced analytics could shrink production costs and improve batch consistency, especially with machine learning-based reactor control in large facilities. On the application front, new medical devices and therapies demand ever more specialized excipients, putting value on those capable of precise chemical tuning. Unsolved puzzles persist, like better modeling of in vivo metabolism and clearer links between molecular structure and patient outcomes. The compound’s carbon-metal backbone holds possibility outside pharma too, including specialty polymers and smart coatings. As market needs shift and regulatory science matures, there’s little chance the pace of discovery will slow.
Most people don’t think about chemicals like Oleic Acid Polyoxometalate when they pick up a bottle of medicine or skin cream. Years ago, I toured a pharmaceutical lab and noticed how scientists kept a close eye on the tiniest differences in raw materials. Purity, consistency, and safety weren’t just buzzwords; they kept patients safe and made treatments work the way doctors promised. Oleic Acid Polyoxometalate, made to BP, EP, and USP pharma grade standards, sits right in the middle of that effort. Each abbreviation—British, European, and US Pharmacopeia—signals the highest levels of chemical safety and quality. So, what does this substance do?
Processed drugs rarely contain a single ingredient. Manufacturers run into challenges blending active pharmaceutical ingredients and getting them to perform in the body as intended. Oleic Acid Polyoxometalate steps in as a reliable helper, often as an excipient. Think of it as the “support crew” for a medicine’s star player. Chemically, this compound brings more than fat content; it improves the way a drug dissolves, making treatments more predictable in their effects. Tablets shouldn’t stick together or become hard as chalk, and proper mixing ensures smooth delivery and shelf stability—not just for a few days, but for months or even years.
Skin creams and ointments often carry a therapeutic promise but fall short without the right formulation. I’ve seen pharmacists struggle over the years with balms that separated or failed to deliver active substances deep enough. Oleic Acid Polyoxometalate acts as an emulsifier and penetration enhancer. It helps oil and water combine, maintaining a product's structure and making medicines soak into the skin rather than washing away. Clinical reports back this up; researchers in dermatology highlight these benefits in journals devoted to transdermal delivery.
Pharma-grade isn't just a fancy label. Contaminants can create real risk. Standards set by BP, EP, and USP call for batch-after-batch testing for heavy metals, moisture, and other threats. Regulatory watchdogs in the US, Europe, and Asia look for these certifications before approving drugs and therapies for the market. Hospitals and doctors trust drugs that include these excipients because these chemicals carry less risk of causing allergic reactions or dangerous side effects compared to lower grades. Medical recalls have taught everyone that attention to detail at the chemical level matters to public health.
Labs rely on this compound for developing new drugs. Often, formulations must mimic the body’s natural pathways—something easier to achieve with quality excipients. Oleic Acid Polyoxometalate has a proven track record supporting hits in pain relief, hormone therapies, and chronic disease management. Even small changes in the excipient layer can make or break a new product moving from clinical trials to pharmacy shelves.
Demand for traceable, pure ingredients like Oleic Acid Polyoxometalate keeps growing, not just from big pharma but also from small compounding pharmacies and innovative startups working on personalized treatments. Supply chain transparency can still use work, and companies invest in better sourcing and smarter tracking systems. Setting a high bar for the chemical building blocks underpins progress in medicine and keeps the trust that patients place in their prescriptions strong. Every step, from lab bench to bedside, counts.
Manufacturing chemicals for drug production calls for more than simple purity. Let's consider oleic acid polyoxometalate as an example. This compound finds use where precision and safety cannot slip. In pharmaceutical contexts, three key pharmacopeias set the bar: British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP).
Each pharmacopeia expects oleic acid polyoxometalate to show specific purity markers. For BP, EP, and USP, developers test for identity, appearance, and absence of harmful by-products. A quick check at any pharmaceutical company's laboratory would reveal that purity — typically exceeding 99% — is non-negotiable. Lower levels compromise both quality and safety.
Contaminants get sharp scrutiny. Metals, water content, free fatty acids, and residual solvents must fall below strict thresholds. Both BP and EP require documentation for trace metals, with limited parts-per-million allowed for heavy metals such as lead and arsenic. Moisture matters as well, and titration or Karl Fischer analyses provide assurance that water content sits under 0.5%. No one in the business of medicine trusts 'almost dry.' Free acid in oleic acid polyoxometalate can pose issues, so limits on acid value remain tight. USP and EP both place values in the range of 1.0 to 3.0 mg KOH/g for acid value, reflecting the importance of consistent chemical behavior.
Every batch must match the reference molecule precisely. Pharmacopeias demand that melting point, IR spectrum, and chromatographic profile do not drift from what’s written in their monographs. A test in a good analytical lab reveals real-world differences—impurities, chain length variation, maybe signs of oxidation. Regulatory authorities watch for these problems because small changes can scale up into major risks.
For polyoxometalate-based compounds, checks on oxidation state and exact stoichiometry matter. EP outlines tests for specific metal content, requiring tools like ICP-MS or atomic absorption spectroscopy. These tools report whether metallic ions are right where they should be. Any drift away from the monograph’s reference throws the product out of spec.
Documentation and batch release certificates hold as much weight as the chemistry itself. In my own experience, regulatory inspections pick apart traceability. No batch passes without full identity, purity, and impurity profiles. Routine audits favor suppliers and manufacturers who control every process — from raw material sourcing to final batch.
Suppliers try to meet or beat both BP and USP limits, knowing that patient health can depend on routine QC tests that catch out-of-spec product before it enters the supply chain. The cost of recall or failure stretches well beyond damaged reputation — failed drugs also mean missed treatment and lost trust, which are impossible to unwind.
Tighter collaboration between raw material suppliers and pharmaceutical manufacturers cuts down on off-spec deliveries. Real-time batch analytics — using advanced spectrometry and chromatography — lets labs catch deviations early. Investing in equipment for detecting trace impurities creates a strong line of defense.
Building expertise with regulatory documents doesn’t just speed up audits — it shields both patients and practitioners from unnecessary risk. In my years working with compliance teams, the best results have come from clear procedures, data-rich certificates, and quick resolution when test results dig up problems. Patients down the line benefit from stubborn attention to these purity requirements.
People often forget how much trust rides on every inactive ingredient found in tablets, capsules, and ointments. Oleic acid polyoxometalate, known for surfactant properties and found under BP, EP, and USP pharma grades, lands right at the crossroads of medicine manufacturing. There’s a lot at stake. The pharma grade tag means the product meets strict pharmacopoeia standards, so labs control impurities, toxicity, and stability. Patients ought to know the story doesn’t end with standard checks on paper.
Through years in pharmacy settings, I’ve seen the consuming concern among practitioners about even minor ingredients. The pharmacopoeia grades can look reassuring—these standards come from regular reviews by expert panels, with sharp eyes on contaminant profiles and purity levels above 99%. Regulators force suppliers to document every lot, trace the origin of raw materials, and share data on possible heavy metal residues. Oleic acid used for drugs isn’t the same as food- or technical-grade material. Manufacturing processes get optimized to strip out pesticides, solvents, and unwanted byproducts, especially with polyoxometalates that can carry traces of transition metals.
But paper standards don’t dissolve the anxiety practitioners feel about newer or less-familiar ingredient combinations. The safety case usually stands on three legs: toxicity data, history of medical use, and real-world batch consistency. Toxicological studies focused on rats and mice show oleic acid, in these pharmaceutical forms, gets broken down by enzymes in the body. Even at high doses, the compound seems less likely to trigger systemic issues compared to other surfactants. Allergic reactions rarely show up in literature.
Still, gaps exist. In real-world hospital settings, not all patients react the same way, especially with new chemical entities. People with rare metabolic conditions, for example, still land in grey areas that studies can miss. That’s where pharmacovigilance fills the gap—practitioners flag side effects and adverse reactions, and data goes back to the manufacturers and regulators. Electronic health records have made it much easier to spot trends, even with supposedly safe pharma-grade materials.
In the end, clean safety records for materials like Oleic acid polyoxometalate rely on two things: traceability and ongoing oversight. Inspectors walk through supplier sites, audit production records, and pull random samples. Batches can get rejected, even on the slightest suspicion of contamination. QA teams in pharmaceutical plants send regular updates to national and international oversight bodies. Patients are increasingly asking for this transparency.
No system eliminates risk, but the current pharma-grade process means contaminants stay below safe thresholds for nearly all users. Manufacturers who use this ingredient can boost peace of mind by running extra in-house analyses for heavy metals or unknown residues, and sharing test results. Pharmacists can keep reporting outcomes, especially in sensitive patient groups. Doctors and patients deserve to see ingredient breakdowns and data—not just trust a label stamp. Openness across the chain, from ingredient batch to pharmacy shelf, supports everyone who counts on treatment that works without hidden danger.
Working in labs and pharma plants, I’ve seen chemicals get ruined simply because a lid got left cracked or a drum survived a summer in a humid corner. Oleic Acid Polyoxometalate might sound intimidating, but its safety isn’t so different from storing other specialty chemicals. It deserves genuine attention, mostly because it goes into medicines. In pharmaceutical settings, attention to proper storage isn’t a luxury – it keeps drugs safe and patients protected.
If you talk to any quality manager, the first thing they check is temperature control. Pharma-grade oleic acid polyoxometalate prefers cool, dry storage. Moisture encourages breakdown. A well-sealed container matters just as much as keeping things cool. Most facilities use tightly fitted drums or high-grade polyethylene containers, which provide a solid barrier against both moisture and air.
Air is just as big an enemy as water. Left exposed, this compound oxidizes faster, cutting its shelf life short. Anyone who’s seen a discolored batch knows that once the product gets off-color, the whole lot might end up in the disposal bin. Protecting the chemical from light makes sense too because UV rays help drive unwanted changes, even over just a few sunny days. Dedicated storerooms use UV-blocking fixtures or, at the least, keep lights low and packaging opaque.
Plenty of folks skip gloves and goggles with chemicals that look tame, but safety routines pay off here. Skin contact can irritate. Fumes from sloppy pours can catch sensitive airways. Site rules always call for lab coats, gloves made of nitrile, and full goggles while dispensing or mixing. It’s worth remembering that pharmacy employees get certain chemical exposures every day. Small errors add up.
Staff turnover in warehouses and labs means not everyone understands the compound on day one. A thorough rundown of what not to do with oleic acid polyoxometalate beats online modules hands down. Showing new hires what a spill looks like, how to seal a drum, and what to write on tracking sheets keeps everyone on the same page.
Imagine grabbing the wrong barrel because the label smudged or fell off. Labels printed with the correct chemical name, lot number, supplier, and arrival date are a site’s first defense. Tracking temperature logs lets facilities catch slips before a product batch moves out to the next customer. Pharmacies trust in consistent labeling every day. It’s not up for debate during audits or product recalls.
Spills of this chemical might seem minor, but a small puddle on a loading dock slicks things up or damages concrete. Staff mop-up routines make a difference. Designated absorbents and chemical-resistant bins simplify the cleanup. Wasting less product always comes back to good storage – using FIFO (first in, first out), checking expiration dates, and removing old drums before leaks begin. Daily walk-arounds catch leaks early. I’ve seen fewer accidents where teams take that time.
Teams that ask questions about suit-up routines and schedule regular storeroom checks tend to have fewer headaches. Smart labs keep a log near the door and task shifts with visual checks. In tight spaces, metal shelving raises barrels off the concrete, helping prevent corrosion.
Facility upgrades cost money but pay off quickly—automatic temperature alarms, humidity sensors, and UV shielding stop most common problems before they snowball. Extra training, regular stock rotation, and better labels cost less than wasted batches or hazard pay after a spill. Dispensing audits often highlight where staff take shortcuts. Fixing these lapses in real time reduces incidents and keeps the chemical viable longer.
Whenever a pharmaceutical ingredient lands on the lab bench or production floor, workers start checking the basics. Is it stable? Will it hold up through transport, storage, and actual use? Oleic Acid Polyoxometalate, made to meet BP, EP, and USP standards, is no exception. For pharma-grade quality, this compound usually carries a shelf life of two years under proper conditions, though some manufacturers specify up to three years with ideal packaging and cool storage.
The shelf life comes down to chemical stability and purity—a batch that sits too long risks oxidation or moisture uptake. Even the world’s best batch falls short if it picks up water or starts reacting with light in a warm warehouse. Exposure to air and fluctuating temperatures can push degradation, leading to shifts in physical appearance, odd odors, or worse, out-of-spec assay values. Losing control over those factors hurts drug safety and leaves manufacturing teams facing unnecessary costs.
Pharma-grade packaging goes way beyond just keeping powder or liquid contained. For Oleic Acid Polyoxometalate, strong, wide-mouth HDPE drums with tamper-evident seals tend to be the norm for bulk. Smaller pharma units often arrive in double-sealed, opaque containers. This approach guards against light, limits air ingress, and squeezes out the risk of cross-contamination.
Every mile of distribution can introduce new threats—fluctuating humidity, accidental drops, contamination from nearby chemicals. I’ve seen careful QA techs run hands along drum edges or lift up seals, scanning for even a tiny sign of puncture. This stops potential disasters before they become batch-wide recalls or—far worse—issues that reach the patient.
Why HDPE? High-density polyethylene stands up to acids while keeping out light and air far better than low-grade plastics. Smart manufacturers also stamp each drum with clear batch numbers, manufacturing dates, and recommended expiry. These details sound basic, but in a recall, a worker’s ability to quickly identify at-risk inventory can mean the difference between quick action and regulatory headaches.
Even with immaculate packaging, the warehouse environment counts. Stability studies recommend keeping Oleic Acid Polyoxometalate sealed, in a cool, dry spot. Pharma facilities often target storage between 15°C and 25°C, away from direct sunlight or industrial heat sources. Some invest in data-logging thermometers; others run checklists before staff sign off storage conditions at shift changes.
Packaging only does half the work: warehouse standards and handling culture do the rest. When teams treat every drum or container as a potential weak link, waste drops. Company trust levels rise with every batch traced—from drum right down to daily records posted on warehouse boards.
Advances in barrier films and smarter sensors point the way to longer shelf life and stronger product stability in the coming years. Some vendors already experiment with layered polymer-laminates offering both chemical resistance and real-time monitoring for temperature spikes. Investing in better employee training means fewer accidental exposures and more consistent adherence to protocols.
Consistent quality from raw material to finished pharmaceutical depends on getting both packaging design and storage routines right. Lessons learned from one failed batch or recall make a difference for years. Focusing on storage and handling doesn’t just safeguard shelf life of Oleic Acid Polyoxometalate; it protects the entire chain from production floor to hospital pharmacy shelf.
| Names | |
| Preferred IUPAC name | octadec-9-enoic acid |
| Other names |
cis-9-Octadecenoic acid 9-Octadecenoic acid (Z)- Octadec-9-enoic acid Red oil Elaidic acid (trans-isomer) Pharmagrade oleic acid cis-Delta-9-octadecenoic acid |
| Pronunciation | /oʊˈleɪɪk ˈæsɪd ˌpɒliˌɒksəʊˈmɛt.əˌleɪt biː piː iː piː juː ɛs piː ˈfɑːrmə ɡreɪd/ |
| Identifiers | |
| CAS Number | 112-80-1 |
| Beilstein Reference | 1721706 |
| ChEBI | CHEBI:36444 |
| ChEMBL | CHEMBL1429652 |
| ChemSpider | 2036809 |
| DrugBank | DB04224 |
| ECHA InfoCard | ECHA InfoCard: 100.003.463 |
| EC Number | EC 200-490-9 |
| Gmelin Reference | 80038 |
| KEGG | C00712 |
| MeSH | D008074 |
| PubChem CID | 445639 |
| RTECS number | RG7790000 |
| UNII | 8OC22C1B99 |
| UN number | UN3265 |
| CompTox Dashboard (EPA) | DTXSID9024263 |
| Properties | |
| Chemical formula | C18H34O2 |
| Molar mass | 282.47 g/mol |
| Appearance | Clear, colorless to pale yellow oily liquid |
| Odor | Odorless |
| Density | Density: 0.89 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 8.7 |
| Vapor pressure | Negligible |
| Acidity (pKa) | pKa 4.75 |
| Basicity (pKb) | 15.6 |
| Magnetic susceptibility (χ) | −8.0×10−6 cm³/mol |
| Refractive index (nD) | 1.453 |
| Viscosity | 35 - 40 cPs |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 653.1 J/mol·K |
| Std enthalpy of combustion (ΔcH⦵298) | -2828 kJ/mol |
| Pharmacology | |
| ATC code | A16AX |
| Hazards | |
| GHS labelling | GHS02, GHS07, Danger, H315, H319, H335 |
| Pictograms | GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | Hazard statements: Causes serious eye irritation. Causes skin irritation. |
| Precautionary statements | P280, P305+P351+P338, P337+P313 |
| NFPA 704 (fire diamond) | 2-1-0 |
| Flash point | 220°C |
| Autoignition temperature | 385°C |
| Lethal dose or concentration | Lethal dose or concentration not established. |
| LD50 (median dose) | LD50 (median dose): >5000 mg/kg (oral, rat) |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for Oleic Acid Polyoxometalate BP EP USP Pharma Grade: Not specifically established. |
| REL (Recommended) | 5 mg/kg |
| IDLH (Immediate danger) | Not listed |
| Related compounds | |
| Related compounds |
Stearic Acid Linoleic Acid Polyoxometalates Palmitic Acid Arachidic Acid Erucic Acid Myristic Acid |
Chengguan District, Lanzhou, Gansu, China
